Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer.
Eur J Gynaecol Oncol
; 35(3): 224-9, 2014.
Article
em En
| MEDLINE
| ID: mdl-24984532
ABSTRACT
PURPOSE:
To investigate the effectiveness of platinum-based combination chemotherapy as second-line chemotherapy for patients with advanced or recurrent endometrial cancer treated initially by platinum-based combination chemotherapy. MATERIALS ANDMETHODS:
Subjects were patients who had received platinum-based combination chemotherapy as second-line chemotherapy 56 patients with recurrent disease who had previously received postoperative adjuvant platinum-based combination chemotherapy (Category 1) and 21 patients who had received first-line chemotherapy but not adjuvant chemotherapy for advanced or recurrent disease (Category 2). Patients' records were searched for the response to second-line chemotherapy and survival, particularly in relation to the platinum-free interval (PFI).RESULTS:
APFI over 12 months was a predictor of response (64.7%) and overall survival time (23 months) in Category 1 patients. A PFI of less than three months was a negative predictor of response (0%) and overall survival (nine months) in Category 2 patients.CONCLUSION:
Platinum-based combination chemotherapy appears to be effective as second-line chemotherapy for endometrial cancer if the PFI is sufficiently long.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Endométrio
/
Recidiva Local de Neoplasia
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article